Literature DB >> 17542753

Virus-like particles: flexible platforms for vaccine development.

Bryce Chackerian1.   

Abstract

Virus-like particles (VLPs) consist of viral structural proteins that, when overexpressed, spontaneously self-assemble into particles that are antigenically indistinguishable from infectious virus or subviral particles. VLPs can be considered as dense, repetitive arrays of one or more protein subunits with properties that are highly advantageous for use as stand-alone vaccines or as vaccine platforms. This review discusses the development of VLP-based platform technologies for vaccines against pathogens, as well as nontraditional targets such as self-antigens involved in chronic diseases.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17542753     DOI： 10.1586/14760584.6.3.381

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN： 1476-0584            Impact factor:   5.217


  118 in total

1.  Blood stage merozoite surface protein conjugated to nanoparticles induce potent parasite inhibitory antibodies.

Authors:  Kae Pusic; Hengyi Xu; Andrew Stridiron; Zoraida Aguilar; Andrew Wang; George Hui
Journal:  Vaccine       Date:  2011-09-28       Impact factor: 3.641

2.  Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7.

Authors:  Jerri do Carmo Caldeira; Alexander Medford; Rhonda C Kines; Christopher A Lino; John T Schiller; Bryce Chackerian; David S Peabody
Journal:  Vaccine       Date:  2010-04-29       Impact factor: 3.641

3.  A specific domain of the Chikungunya virus E2 protein regulates particle formation in human cells: implications for alphavirus vaccine design.

Authors:  Wataru Akahata; Gary J Nabel
Journal:  J Virol       Date:  2012-05-30       Impact factor: 5.103

Review 4.  Virus-based nanoparticles as platform technologies for modern vaccines.

Authors:  Karin L Lee; Richard M Twyman; Steven Fiering; Nicole F Steinmetz
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-01-19

5.  Delivery strategies for novel vaccine formulations.

Authors:  Maria Trovato; Shelly J Krebs; Nancy L Haigwood; Piergiuseppe De Berardinis
Journal:  World J Virol       Date:  2012-02-12

6.  Induction of mucosal and systemic antibody responses against the HIV coreceptor CCR5 upon intramuscular immunization and aerosol delivery of a virus-like particle based vaccine.

Authors:  Zoe Hunter; Hugh D Smyth; Paul Durfee; Bryce Chackerian
Journal:  Vaccine       Date:  2009-10-20       Impact factor: 3.641

7.  Proteomic characterization of influenza H5N1 virus-like particles and their protective immunogenicity.

Authors:  Jae-Min Song; Chi-Won Choi; Sang-Oh Kwon; Richard W Compans; Sang-Moo Kang; Seung Il Kim
Journal:  J Proteome Res       Date:  2011-07-08       Impact factor: 4.466

8.  An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.

Authors:  Akane Urakami; Mya Myat Ngwe Tun; Meng Ling Moi; Atsuko Sakurai; Momoko Ishikawa; Sachiko Kuno; Ryuji Ueno; Kouichi Morita; Wataru Akahata
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

9.  Immunogenicity of H1N1 influenza virus-like particles produced in Nicotiana benthamiana.

Authors:  Yoko Shoji; Alex Prokhnevsky; Brett Leffet; Nancy Vetter; Stephen Tottey; Shama Satinover; Konstantin Musiychuk; Moneim Shamloul; Joey Norikane; R Mark Jones; Jessica A Chichester; Brian J Green; Stephen J Streatfield; Vidadi Yusibov
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

Review 10.  Finding the sweet spots of inhibition: understanding the targets of a functional antibody against Plasmodium vivax Duffy binding protein.

Authors:  Francis B Ntumngia; Christopher L King; John H Adams
Journal:  Int J Parasitol       Date:  2012-10-12       Impact factor: 3.981
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.